OpenBilldrug price receipt

NADAC week of 2026-10-14

METHOTREXATE 250 MG/10 ML VIAL

For 10 mL

Pharmacies pay

$7.02 – $31.83 filed

10 × $0.702 to $3.1832 per ML (the 3 NDCs differ)

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part B pays

$14.55 derived

10 × $1.4545 per ML, Part B limit

Medicare's price is not your price.

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)


The spread

0.46× – 2.1× estimated

Medicare pays between 0.46× and 2.1× what pharmacies pay, depending on the NDC.

5 labelers share HCPCS J9260 on the CMS crosswalk, so its payment limit is an average across all their products billed under that code, not this NDC’s own price. (Counted once each though written more than one way: “ACCORD HEALTHCARE INC” and “Accord Healthcare Inc”.)

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Cost-plus estimate

$13.07 – $41.60 estimated

NADAC for the pack + 15% + $5.00 fee per fill

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

METHOTREXATE 250 MG/10 ML VIAL is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “methotrexate sodium” and “methotrexate”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as “injection, solution” and “injection” and its route as “intra-arterial; intramuscular; intrathecal; intravenous” and “intra-arterial; intramuscular; intravenous”.

Its labelers, the companies named on the label, are Teva Parenteral Medicines, Inc., Accord Healthcare, Inc. and Fresenius Kabi USA, LLC.

FDA’s Established Pharmacologic Class for it is Folate Analog Metabolic Inhibitor.

The NADAC file of 2026-10-14 prices it under 3 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $7.02 – $31.83 for 10 mL, depending on the NDC ($0.702 to $3.1832 per ML), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

All 3 NDCs

Other strengths, forms and brands

13 other products in the NADAC file share an FDA nonproprietary name with METHOTREXATE 250 MG/10 ML VIAL.

ProductPharmacies pay per unitMedicare per unit
METHOTREXATE 2.5 MG TABLET
generic · tablet
$0.15774 per EA filed
eff. 2026-09-23
$0.157 per EA derived
Part B limit 2026 Q4
METHOTREXATE 50 MG/2 ML VIAL
generic · solution / injection, solution / injection
$1.23696 to $3.1832 per ML filed
eff. 2026-09-23
$1.4545 per ML derived
Part B limit 2026 Q4
METHOTREXATE 250 MG/10 ML VIAL this page
generic · injection, solution / injection
$0.702 to $3.1832 per ML filed
eff. 2026-09-23
$1.4545 per ML derived
Part B limit 2026 Q4
RASUVO 7.5 MG/0.15 ML AUTOINJ
brand · injection, solution
$960.29324 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 10 MG/0.2 ML AUTOINJ
brand · injection, solution
$721.8144 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 12.5 MG/0.25 ML AUTOINJ
brand · injection, solution
$574.86795 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 15 MG/0.3 ML AUTOINJ
brand · injection, solution
$480.00227 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
RASUVO 17.5 MG/0.35 ML AUTOINJ
brand · injection, solution
$409.92919 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 20 MG/0.4 ML AUTOINJ
brand · injection, solution
$362.2851 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
RASUVO 25 MG/0.5 ML AUTOINJ
brand · injection, solution
$289.365 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
TREXALL 5 MG TABLET
brand · tablet, film coated
$24.08844 per EA filed
eff. 2026-01-01
$41.73652 per EA filed
Part D 2024 average
TREXALL 7.5 MG TABLET
brand · tablet, film coated
$36.20914 per EA filed
eff. 2026-02-18
$41.73652 per EA filed
Part D 2024 average
TREXALL 10 MG TABLET
brand · tablet, film coated
$48.13525 per EA filed
eff. 2026-09-23
$41.73652 per EA filed
Part D 2024 average
XATMEP 2.5 MG/ML ORAL SOLUTION
brand · solution
$21.76353 per ML filed
eff. 2026-09-23
$19.76312 per ML filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. between 2026-01-01 and 2026-09-23 (4 dates) · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 3 NDCs’ NADAC prices is $0.702 per ML filed.

Of the 9 other products in FDA’s Folate Analog Metabolic Inhibitor class priced per ML, 9 have a higher middle NADAC price and 0 a lower one. The one in the middle is RASUVO 17.5 MG/0.35 ML AUTOINJ, at $409.92919 per ML filed (eff. 2026-04-01).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part B’s payment limit for HCPCS J9260, for 2026-10-01 to 2026-12-31, comes to $14.55 for 10 mL, or $1.4545 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.5818 per 50 MG.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why does this page start at 10 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 10 mL in one package for all 3 NDCs of this product (“1 VIAL, SINGLE-DOSE in 1 CARTON (0703-3675-01) / 10 mL in 1 VIAL, SINGLE-DOSE”), so the card starts at one package: 10 ML. Change it to match your prescription.